Webinars & Presentations Overcome the limitations of conventional transfection with MaxCyte electroporation

Overcome the limitations of conventional transfection with MaxCyte electroporation

This webinar is for scientists who are struggling to meet the demands of cell engineering in various applications, including cell therapy, cell-based screening and bioproduction.

October 30, 2024

Peter Gee, PhD, Senior Field Applications Scientist at MaxCyte, presents on how traditional delivery methods, such as chemical transfection and retroviral transduction, compare to electroporation for transient and stable engineering with plasmid DNA, mRNA and CRISPR-RNPs.

Are low gene editing efficiency or gene expression levels preventing your research from advancing?

Is your transfection method killing your cells?

Are you struggling to reproduce your initial results when you attempt to transfect millions of cells instead of thousands?

Join us as we explore how MaxCyte's electroporation technology can help you to overcome these challenges. Learn how traditional delivery methods, such as chemical transfection and retroviral transduction, compare to electroporation for transient and stable engineering with plasmid DNA, mRNA and CRISPR-RNPs. We will also introduce new approaches for larger-scale electroporation that enable faster workflows, which can save researchers weeks of development time.

Watch the webinar

Presenter

Peter Gee, PhD

Senior Field Applications Scientist at MaxCyte

Peter Gee is a Senior Field Applications Scientist at MaxCyte specializing in gene editing and stem cell technologies. Following a B.S. in biochemistry and molecular biology at the University of California, Davis, Peter served as a Research Associate in the Biochemical Pharmacology Core Group at Roche Palo Alto investigating small molecule drugs against viral enzymes. After completing a PhD at the Institute for Virus Research, Kyoto University, Peter did his postdoctoral training in the laboratory of Akitsu Hotta at Kyoto University’s Center for iPS Cell Research and Application where he developed delivery vehicles of CRISPR-Cas9 ribonucleoprotein complexes utilizing engineered extracellular nanoparticles.